What does low or absent natural killer (NK) cell activity indicate in hemophagocytic lymphohistiocytosis (HLH) and how should it be managed?

Low or Absent NK Function in HLH

Low or absent natural killer (NK) cell activity is one of the eight diagnostic criteria for hemophagocytic lymphohistiocytosis (HLH) and serves as a key immunologic marker supporting the diagnosis when present alongside other clinical and laboratory findings. 1

Diagnostic Significance

NK cell dysfunction in HLH reflects the underlying pathophysiology of impaired cytotoxic immune function. According to the HLH-2004 diagnostic criteria, the diagnosis requires meeting 5 of 8 criteria, with low/absent NK cell activity (according to local laboratory reference) being one of these criteria 1, 2. This criterion was added to the original HLH-94 criteria specifically to capture the immunologic dysfunction characteristic of this syndrome.

Key Points About NK Testing:

• NK cell activity should be measured by flow cytometry-based assays using K562 target cells, with optimal effector-to-target ratios of 10:1 and 4-hour incubation times 3
• Reference intervals vary by laboratory, but healthy individuals typically show NK cytotoxicity of approximately 20-31% 4
• HLH patients demonstrate significantly reduced NK activity (mean 8-12%) compared to non-HLH febrile patients (20-26%) 5, 6
• Primary HLH patients show even lower NK activity (10.8%) than secondary HLH patients (15.0%) 3

Important Caveats:

While NK cell dysfunction is characteristic of HLH, its diagnostic specificity in adults is limited - the test has high sensitivity (92-96%) but borderline discriminatory power for HLH diagnosis in adults 5, 6. Many febrile conditions with cytopenia can show decreased NK function. Therefore, NK cell activity should never be used in isolation but must be interpreted within the complete clinical context and alongside other HLH-2004 criteria 1.

Management Approach

Immediate Actions When Low NK Activity is Detected:

1. Complete the HLH-2004 diagnostic workup immediately:

   • Ferritin (target >500 μg/L, highly suspicious if >10,000 μg/L)
   • Soluble IL-2 receptor/sCD25 (≥2,400 U/mL)
   • Triglycerides (≥265 mg/dL) and fibrinogen (≤1.5 g/L)
   • Document fever, splenomegaly, cytopenias (≥2 lineages)
   • Bone marrow examination for hemophagocytosis 1

2. Aggressively search for underlying triggers - this must continue even during HLH treatment 1:

   • Infections (most common): EBV, CMV, other viral/bacterial pathogens
   • Malignancies (especially in adults): T-cell/NK-cell lymphomas (35%), B-cell lymphomas (32%), leukemias
   • Autoimmune/autoinflammatory diseases: Still's disease, lupus, vasculitis
   • Perform genetic testing for familial HLH genes (PRF1, UNC13D, STX11) 1

3. Initiate treatment promptly if ≥5 criteria are met (or even if <5 criteria with strong clinical suspicion) 1:

Treatment Algorithm:

For Secondary HLH (acquired, no genetic mutation):

• Start high-dose corticosteroids immediately - do not delay, particularly with organ dysfunction 7
• If inadequate response in macrophage activation syndrome: add IL-1 inhibition and/or cyclosporine A 7
• For severe, persistent, or relapsing disease: add individualized etoposide (age-adjusted dosing) 7
• Treat the underlying trigger aggressively (antimicrobials for infection, chemotherapy for malignancy) 1

For Primary/Familial HLH (genetic mutation confirmed):

• HLH-2004 protocol: etoposide + dexamethasone + cyclosporine A upfront 2
• Intrathecal therapy (methotrexate + corticosteroids) for CNS involvement 2
• Plan for hematopoietic stem cell transplantation - this is definitive therapy for familial disease 2, 7

For NK-cell malignancy-associated HLH:

• Asparaginase-containing lymphoma regimens are superior to etoposide-based HLH therapy alone for both overall survival and 60-day outcomes 8
• This represents a critical exception to standard HLH treatment protocols

Prognostic Considerations:

In non-malignant secondary HLH, low NK cytotoxicity correlates with poor survival outcomes 6. However, the most important prognostic factors are:

• Underlying malignancy (worst prognosis) 6
• High ferritin levels 6
• Platelet count <20 × 10⁹/L 8
• ECOG performance status ≥2 8
• Serum albumin <30 g/L 8

Common Pitfalls to Avoid:

• Do not wait for NK cell results to initiate treatment if other criteria strongly suggest HLH and the patient is deteriorating
• Do not rely solely on NK testing for diagnosis - it has limited specificity in adults 6
• Do not miss underlying malignancy - maintain high suspicion especially in older adults, as lymphomas are a major HLH trigger 1
• Do not delay genetic testing - results guide transplant decisions and family counseling 1, 9
• Do not use standard HLH protocols for NK-cell lymphoma-associated HLH - these patients require asparaginase-based regimens 8

The combination of low NK activity with ferritin >10,000 μg/L provides excellent diagnostic specificity (94.2%) for ruling out HLH when both are absent 5.